Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
September 26 2023 - 7:58AM
Business Wire
-- Presentation on Tuesday, October 3rd at 12
PM PT --
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”)
(NASDAQ: VRPX), a company specializing in developing
non-addictive products for pain management, post-traumatic stress
disorder, central nervous system (CNS) disorders and viral barrier
indications, today announced that it will be presenting at the 16th
annual Main Event on Tuesday, October 3rd at 12:00 PM PT at the
Luxe Sunset Boulevard Hotel. Anthony P. Mack, Chairman and CEO will
be giving the presentation.
Event: LD Micro Main Event XVI Date: Tuesday,
October 3rd Time: 12:00 PM PT
Register to watch the virtual presentation here.
Summary of LD Micro Main Event XVI
The 2023 LD Micro Main Event XVI will run from October 3rd to
the 5th at the Luxe Sunset Boulevard Hotel in Los Angeles.
Presentations will run from 8:00 AM PT to 5:00 PM PT on the 3rd
and 4th, with a half day on Thursday the 5th.
This three-day event will feature around 200 companies,
presenting in half-hour increments, and attending private meetings
with investors.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management
products candidates using its proprietary technologies to optimize
and target drug delivery. Virpax is initially seeking FDA approval
for two prescription drug candidates that employ two different
patented drug delivery platforms. Probudur™ is a single injection
liposomal bupivacaine formulation being developed to manage
post-operative pain and Envelta™ is an intranasal molecular
envelope enkephalin formulation being developed to manage acute and
chronic pain, including pain associated with cancer. Virpax is also
using its intranasal Molecular Envelope Technology (MET) to develop
two other product candidates. PES200 is a product candidate being
developed to manage post-traumatic stress disorder (PTSD) and
NobrXiol™ is a product candidate being developed for the nasal
delivery of a pharmaceutical-grade cannabidiol (CBD) for the
management of rare pediatric epilepsy. Virpax recently acquired
global rights to NobrXiol. Virpax is also seeking approval of two
nonprescription product candidates: AnQlar, which is being
developed to inhibit viral replication caused by influenza or
SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray
film formulation being developed to manage pain associated with
osteoarthritis. For more information, please visit virpaxpharma.com
and follow us on Twitter, LinkedIn and YouTube.
About LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was
founded in 2006 with the sole purpose of being an independent
resource in the micro-cap space. Through the LD Micro Index and
annual investor conferences, LD has served as an invaluable asset
to all those interested in discovering the next generation of great
companies. For more information on LD Micro, visit
www.ldmicro.com.
To present or register, please contact
registration@ldmicro.com.
To learn more about Freedom US Markets, visit
www.freedomusmkts.com.
For further information on Virpax Pharmaceuticals, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926850663/en/
Investor Relations: Betsy
Brod Affinity Growth Advisors Betsy.brod@affinitygrowth.com (917)
923-8541
Media: Robert Cavosi
RooneyPartners rcavosi@rooneypartners.com (646) 638-9891
Virpax Pharmaceuticals (NASDAQ:VRPX)
Historical Stock Chart
From May 2024 to Jun 2024
Virpax Pharmaceuticals (NASDAQ:VRPX)
Historical Stock Chart
From Jun 2023 to Jun 2024